Gemtuzumab ozogamicin

Gemtuzumab ozogamicin (pronunciation: gem-too-zoo-mab oh-zoh-ga-mye-sin) is a chemotherapeutic agent used in the treatment of acute myeloid leukemia (AML).

Etymology

The name "Gemtuzumab" is derived from "Gem" referring to gemtuzumab, the monoclonal antibody used in the drug, and "ozogamicin" referring to the antibiotic calicheamicin, which is the cytotoxic agent attached to the antibody.

Usage

Gemtuzumab ozogamicin is used as a targeted therapy for CD33-positive AML. CD33 is a protein found on the surface of these leukemia cells. The drug works by binding to the CD33 protein and delivering the cytotoxic agent directly to the leukemia cells, sparing healthy cells.

Related Terms

• Monoclonal antibody
• Chemotherapeutic agent
• Acute myeloid leukemia
• CD33
• Cytotoxic agent

Side Effects

Like all chemotherapeutic agents, gemtuzumab ozogamicin can have side effects. These can include fever, nausea, and low blood cell counts. More serious side effects can include liver problems and infusion reactions.

See Also

• Chemotherapy
• Targeted therapy
• Leukemia

External links

• Medical encyclopedia article on Gemtuzumab ozogamicin
• Wikipedia's article - Gemtuzumab ozogamicin

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski